Sugi Predict

Sugi Predict / Compounds / SCHEMBL4490261

SCHEMBL4490261

SCHEMBL4490261

COC(=O)c1cc(O)[nH]n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.67
▸ POLB P06746 3/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ HCAR2 Q8TDS4 5/20 0.44
▸ KDM4C Q9H3R0 1/20 0.43
▸ DAO P14920 1/20 0.42
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA7 P43166 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ CA14 Q9ULX7 1/20 0.41
▸ GAA P10253 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ NFKB1 P19838 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL68056 0.80 MAPK1 (1.00) MAPK1POLBRAB9ANPC1L3MBTL1
SCHEMBL163583 0.80 MAPK1 (0.67) MAPK1POLBRAB9ANPC1L3MBTL1
SCHEMBL3624738 0.80 MAPK1 (0.67) MAPK1POLBRAB9ANPC1L3MBTL1
SCHEMBL1423671 0.79 KMT2A (0.54) MAPK1POLBL3MBTL1KMT2AHCAR2
SCHEMBL23013382 0.78 MAPK1 (0.65) MAPK1POLBRAB9ANPC1L3MBTL1
SCHEMBL30614240 0.78 MAPK1 (0.96) MAPK1POLBRAB9ANPC1L3MBTL1
SCHEMBL1009738 0.78 MAPK1 (0.65) MAPK1POLBRAB9ANPC1L3MBTL1
SCHEMBL15555211 0.78 MAPK1 (0.65) MAPK1POLBRAB9ANPC1L3MBTL1
SCHEMBL20517900 0.78 MAPK1 (0.65) MAPK1POLBRAB9ANPC1L3MBTL1
SCHEMBL1267225 0.77 MAPK1 (0.79) MAPK1POLBRAB9ANPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12319703-B2 Macrocyclic fused pyrazoles as Mcl-1 inhibitors ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2025-06-03 — — US disclosed
WO-2025061035-A1 BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF 南京再明医药有限公司 2025-03-27 — — WO disclosed
WO-2023247596-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2023-12-28 — — WO disclosed
CN-115667237-A Novel heterocyclic compounds as BET inhibitors 成都苑东生物制药股份有限公司 2023-01-31 — — CN disclosed
CN-112204036-B Macrocyclic fused pyrazoles as MCL-1 inhibitors 苏州亚盛药业有限公司 2022-12-27 — — CN disclosed
US-20220396587-A1 MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2022-12-15 — — US disclosed
WO-2022012456-A1 NOVEL HETEROCYCLIC COMPOUNDS AS BET INHIBITORS CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. (CN) 2022-01-20 — — WO disclosed
WO-2022012456-A1 NOVEL HETEROCYCLIC COMPOUNDS AS BET INHIBITORS CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. (CN) 2022-01-20 — — WO disclosed
EP-3781575-A1 MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS Ascentage Pharma (Suzhou) Co., Ltd. (CN) 2021-02-24 — — EP disclosed
EP-3174886-B1 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES HOFFMANN LA ROCHE (CH) 2021-02-17 — — EP disclosed
US-9840501-B2 Morpholin-pyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2017-12-12 — — US disclosed
US-9790230-B2 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives HOFFMANN-LA ROCHE INC. (US) 2017-10-17 — — US disclosed
EP-3174886-A1 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES F. Hoffmann-La Roche AG (CH) 2017-06-07 — — EP disclosed
US-20170137435-A1 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-05-18 — — US disclosed
EP-3137459-A1 MORPHOLIN-PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2017-03-08 — — EP disclosed
US-20170044145-A1 MORPHOLIN-PYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-02-16 — — US disclosed
WO-2016016292-A1 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2016-02-04 — — WO disclosed
WO-2016015333-A1 2-OXA-5-AZABICYCLO [2.2.1] HEPTAN-3-YL DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2016-02-04 — — WO disclosed
WO-2015165835-A1 MORPHOLIN-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2015-11-05 — — WO disclosed
US-20090325956-A1 Aromatic amine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170137435-A1 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES HCRTR2, HCRTR1, CYP11B2 MAPK1 2439/4885POLB 2293/4885RAB9A 2360/4885
US-20090325956-A1 Aromatic amine derivative and use thereof SCD, SCD5, SMS MAPK1 1689/4885POLB 2804/4885RAB9A 3368/4885
US-20220396587-A1 MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS MCL1, BCL2A1, BCL2L1 MAPK1 908/4885POLB 1832/4885RAB9A 1256/4885
US-20170044145-A1 MORPHOLIN-PYRIDINE DERIVATIVES OPRM1, MC2R, OPRL1 MAPK1 913/4885POLB 3582/4885RAB9A 737/4885
US-12319703-B2 Macrocyclic fused pyrazoles as Mcl-1 inhibitors MCL1, BCL2A1, BCL2L1 MAPK1 874/4885POLB 1583/4885RAB9A 1471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.